Drug industry

Article Abstract:

The drug industry had a highly profitable year in 1996, although not all companies have reported their final annual results. Profits for the larger multinational companies that are research based are also expected to be good in 1997, as well, even though generic drug companies may have difficulties. Industry earnings through 1999-2001 will be driven mainly by a stream of new drugs. Investors should be cautious when evaluating drug company stocks.

Author: Clark, Charles, Butler, Jeremy J., Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Maher, John E.

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1997

Eli Lilly and Co., Pfizer Inc., Pharmacia and Upjohn Inc., PNU, Glaxo Wellcome PLC, SmithKline Beecham Corp. (Philadelphia, Pennsylvania), SBH, Genentech Inc., Warner-Lambert Co., Cygnus Inc., Dura Pharmaceuticals Inc., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., Sicor Inc., Watson Pharmaceuticals Inc., CHIR, DURA, FRX, GENZ, ICN, IMNX, IVX, LLY, MLY, PRGO, PFE, SGP, WLA, GNE, Valeant Pharmaceuticals International, Merck & Company Inc., Rhone-Poulenc Rorer Inc., Neurex Corp., Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, GNSA, SHR, WATS

User Contributions:

Comment about this article or add new information about this topic:

Drug industry

Article Abstract:

The pharmaceutical industry had a superior year in 1995, with many companies reporting revenues and earnings in double digits. Stocks for biotechnology companies increased 80% during the year, and drug stocks appreciated 59% as well. Drug industry earnings are also expected to be in double digits during 1996, outperforming other industries. Consolidation and other factors make drug industry stocks good investments for 1996 and later.

Author: Clark, Charles, Butler, Jeremy J., Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Ramgopal, Lalishwar

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1996

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Biological Product (except Diagnostic) Manufacturing, Drugs, Biochemicals, Biotechnology industry, Biotechnology industries, Chemicals, Biological products, WLAX

User Contributions:

Comment about this article or add new information about this topic:

Subjects list: Economic aspects, Pharmaceutical industry, Drugs, Finance, Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Chiron Corp., AZA, AHP, AMGN, BGEN, BMY, Wyeth

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.

Abstracts

Business, general

Drug industry

Drug industry